Is Jagsonpal Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Is Jagsonpal Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 236 as of 29 September 2026, within its 52-week range of Rs 155.00 to Rs 264.50. Jagsonpal Pharmaceuticals Ltd manufactures and markets branded pharmaceutical formulations.

Jagsonpal Pharmaceuticals sits in the Healthcare sector, and its 15.60% ROE and 34.89x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Jagsonpal Pharmaceuticals

Jagsonpal Pharmaceuticals Ltd manufactures and markets branded pharmaceutical formulations. The stock fell over 2 percent during this session. At a market capitalisation of Rs 1,586 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Jagsonpal Pharmaceuticals the Best Stock in Its Sector?

Jagsonpal Pharmaceuticals makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 15.60% ROE with a 34.89x P/E against the sector's 51.67x Industry P/E. Jagsonpal Pharmaceuticals' 34.89x P/E is below the 51.67x Industry P/E despite a 15.60% ROE, making it look reasonably valued relative to its own quality, though the stock fell over 2 percent during this session.

Metric	Jagsonpal Pharmaceuticals
CMP (NSE)	Rs 235.80
52-Week High / Low	Rs 264.50 / Rs 155.00
Market Cap	Rs 1,586 Cr
P/E (TTM) vs Industry P/E	34.89x vs 51.67x
P/B	5.78
ROE	15.60%
EPS (TTM)	Rs 6.89
Dividend Yield	1.69%
Debt to Equity	0.03

Compare Jagsonpal Pharmaceuticals Against Other Healthcare Sector Stocks

How Jagsonpal Pharmaceuticals Compares Against Its Healthcare Sector Peers

The table below sets Jagsonpal Pharmaceuticals against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Jagsonpal Pharmaceuticals	1,586	34.89	15.60%	0.03
Gufic Biosciences	4,224	57.55	9.66%	0.61
Innova Captab	7,275	47.23	12.92%	0.32
Peer average (2 companies)	-	52.39	11.29%	0.46

Against this peer set, Jagsonpal Pharmaceuticals's 15.60% ROE is above the 11.29% peer average, and its P/E of 34.89x runs below the peer average of 52.39x. Jagsonpal Pharmaceuticals' 34.89x P/E is below the 51.67x Industry P/E despite a 15.60% ROE, making it look reasonably valued relative to its own quality, though the stock fell over 2 percent during this session.

What Makes Jagsonpal Pharmaceuticals Worth Watching in Healthcare

• Well below Industry P/E: A 34.89x P/E against a 51.67x Industry P/E is a discount for a business with a 15.60% ROE.
• Strong ROE, near debt free: A 15.60% ROE alongside a debt to equity ratio of 0.03 reflects an efficient, well-capitalised pharma business.
• Dividend yield: A 1.69% dividend yield adds a modest income component.

Jagsonpal Pharmaceuticals Valuation: Is It Justified?

Jagsonpal Pharmaceuticals' 34.89x P/E is below the 51.67x Industry P/E despite a 15.60% ROE, making it look reasonably valued relative to its own quality, though the stock fell over 2 percent during this session. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is INOX India the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Jagsonpal Pharmaceuticals and other Healthcare sector stocks.

How to Track Jagsonpal Pharmaceuticals Before You Invest

Before deciding whether Jagsonpal Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Jagsonpal Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Jagsonpal Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 15.60% ROE and a P/E of 34.89x against a 51.67x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Jagsonpal Pharmaceuticals the best stock in its sector?

Ans. Jagsonpal Pharmaceuticals has a 15.60% ROE and trades at 34.89x P/E against a 51.67x Industry P/E, and compares above the peer average ROE of 11.29% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Jagsonpal Pharmaceuticals?

Ans. Jagsonpal Pharmaceuticals was trading at Rs 235.80 on the NSE as of 29 September 2026, within its 52-week range of Rs 155.00 to Rs 264.50.

What sector does Jagsonpal Pharmaceuticals belong to?

Ans. Jagsonpal Pharmaceuticals is classified under the Healthcare sector on Univest.

How does Jagsonpal Pharmaceuticals compare to its sector peers on P/E?

Ans. Jagsonpal Pharmaceuticals's P/E of 34.89x is below the 52.39x average of the 2 named peers compared in this article.

What is Jagsonpal Pharmaceuticals's return on equity?

Ans. Jagsonpal Pharmaceuticals reported a return on equity of 15.60%, which is above the 11.29% average of its named peers in this comparison.

Should I invest in Jagsonpal Pharmaceuticals based on its sector position?

Ans. Jagsonpal Pharmaceuticals's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "Is Jagsonpal Pharmaceuticals the best stock in its sector?", "acceptedAnswer": {"@type": "Answer", "text": "Jagsonpal Pharmaceuticals has a 15.60% ROE and trades at 34.89x P/E against a 51.67x Industry P/E, and compares above the peer average ROE of 11.29% in this article's named comparison, so the answer depends on what an investor is prioritising."}}, {"@type": "Question", "name": "What is the current share price of Jagsonpal Pharmaceuticals?", "acceptedAnswer": {"@type": "Answer", "text": "Jagsonpal Pharmaceuticals was trading at Rs 235.80 on the NSE as of 29 September 2026, within its 52-week range of Rs 155.00 to Rs 264.50."}}, {"@type": "Question", "name": "What sector does Jagsonpal Pharmaceuticals belong to?", "acceptedAnswer": {"@type": "Answer", "text": "Jagsonpal Pharmaceuticals is classified under the Healthcare sector on Univest."}}, {"@type": "Question", "name": "How does Jagsonpal Pharmaceuticals compare to its sector peers on P/E?", "acceptedAnswer": {"@type": "Answer", "text": "Jagsonpal Pharmaceuticals's P/E of 34.89x is below the 52.39x average of the 2 named peers compared in this article."}}, {"@type": "Question", "name": "What is Jagsonpal Pharmaceuticals's return on equity?", "acceptedAnswer": {"@type": "Answer", "text": "Jagsonpal Pharmaceuticals reported a return on equity of 15.60%, which is above the 11.29% average of its named peers in this comparison."}}, {"@type": "Question", "name": "Should I invest in Jagsonpal Pharmaceuticals based on its sector position?", "acceptedAnswer": {"@type": "Answer", "text": "Jagsonpal Pharmaceuticals's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor."}}]}